We are all different but medical therapies are not customized: producing a pharmaceutical takes years and costs millions. The solution is Bioprint3rs, a single machine for infinite customizations. By using a 3D printer, it is enough simply to change the formula in order to automate all the research and development processes and then immediately initiate industrial production.
This is enabled by a patented technology, our 3D bioprinter, the only one in the world fully sanitizable in compliance with the Machine Directive.
Our aim is to enable real-time production of organoids for pharmacological testing using the patient's own cells, implantable products for drug release and tissue regeneration (with the form derived from a CAT), or customized tablets for children and the elderly. Furthermore, by distributing the systems all over the world, we can deliver products immediately to all patients in need, simply by downloading a digital formula, thus reducing environmental impact.
Our business model is extremely simple: machines can be ordered and digital formulas downloaded directly from an Internet portal. Authorized retailers carry out installation and further digital formulas can be easily downloaded based on a subscription.
We intend to start with the small market segment of rare diseases. There are 350 million patients in the world and about 200 million of these receive pill based therapies. If we aimed to reach just 1% of the Italian segment, providing one pill per day for 6 months (in reality these treatments foresee lifelong therapy), the cost of our biofactory can be recuperated within 4 years of purchase, considering a return of just one euro per pill.
BioPrint3rs does not just sell pharmaceuticals, it improves quality of life.
, , ,
